Key points of technical review for the registration of SARS-CoV-2 antigen/antibody tests

Bioanalysis. 2021 Jan;13(2):77-88. doi: 10.4155/bio-2020-0219. Epub 2021 Jan 11.

Abstract

Coronavirus disease-2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally since its first report and become a worldwide pandemic. In response to the outbreak of COVID-19, Center for Medical Device Evaluation, NMPA (CMDE) initiated emergency review and approval procedures to accelerate the process of reviewing emergent medical products and issued the Key Points of Technical Review for the Registration of SARS-CoV-2 Antigen/Antibody Tests (Key Points) to provide the requirements on the technical review of the tests. With uncontrolled spread and evolution of COVID-19 in the world, continuous prevention and measurements are necessary for fighting this pandemic and SARS-CoV-2 antigen/antibody tests are still urgently needed. This article is an attempt to expand clarification of the Key Points to wider audiences based on current understanding of SARS-CoV-2 to facilitate the development and application of SARS-CoV-2 antigen/antibody tests.

Keywords: SARS-CoV-2; antibody; antigen; registration; tests.

MeSH terms

  • Antibodies, Viral / analysis*
  • Antigen-Antibody Reactions
  • Antigens, Viral / analysis*
  • COVID-19 / diagnosis*
  • COVID-19 Testing* / instrumentation
  • China
  • Clinical Trials as Topic
  • Cross Reactions
  • Humans
  • Immunoglobulin M / analysis
  • Limit of Detection
  • Pandemics
  • Reference Standards
  • Reproducibility of Results

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Immunoglobulin M